



CODE OF BUSINESS CONDUCT AND ETHICS – AMENDMENTS

Following is a description of amendments to the Code of Business Conduct and Ethics (the “**Code**”) of NGM Biopharmaceuticals, Inc. (the “**Company**”) adopted within the last 12 months.

November 16, 2022 Amendments

On November 16, 2022, the Board of Directors of the Company (the “**Board**”) adopted and approved an updated Code, which applies to all members of the Board and employees (including officers) of the Company. Besides making technical, administrative, and other non-substantive amendments to make the Code more user friendly, the Code:

- updates the procedure on seeking guidance on, and reporting possible violations of, the Code;
- removes the Drug and Alcohol Abuse and Workplace Conduct, Employment Principles and Practices sections, as it is more appropriately addressed in the Employee Handbook; and
- reflects corresponding updates made to the Whistleblower Policy.

The amendment and restatement of the Code took effect upon adoption by the Board and did not result in any waiver, explicit or implicit, of any provision of the Code that was previously in effect. The foregoing summary is qualified in its entirety by reference to the Code, a copy of which is available at <https://ir.ngmbio.com/corporate-governance/documents-charters>.